keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis C antiviral

keyword
https://www.readbyqxmd.com/read/28942625/current-status-of-and-strategies-for-hepatitis-c-control-in-south-korea
#1
REVIEW
Beom Kyung Kim, Eun Sun Jang, Jeong Han Kim, Soo Young Park, Song Vogue Ahn, Hyung Joon Kim, Do Young Kim
Chronic hepatitis C (CHC) is caused by hepatitis C virus (HCV) infection. HCV infection causes acute hepatitis, and the majority of those infected progress to chronic hepatitis, and some of them develop cirrhosis and hepatocellular carcinoma. Transmission of HCV is parenteral, and the major transmission routes include drug abuse, insecure injections or medical procedures, contaminated syringes or needles, sexual contact with an HCV-infected person, vertical infection of newborns by infected mothers, the transfusion of blood or blood products contaminated with viruses, and organ transplants...
September 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28942620/current-status-and-strategies-for-viral-hepatitis-control-in-korea
#2
REVIEW
Dong Hyun Sinn, Eun Ju Cho, Ji Hoon Kim, Do Young Kim, Yoon Jun Kim, Moon Seok Choi
Viral hepatitis is one of major global health challenges with increasing disease burden worldwide. Hepatitis B virus and hepatitis C virus infections are major causes of chronic liver diseases. They can lead to cirrhosis, hepatocellular carcinoma, and death in significant portion of affected people. Transmission of hepatitis B virus can be blocked by vaccination. Progression of hepatitis B virus-related liver diseases can be prevented by long-term viral suppression with effective drugs. Although vaccine for hepatitis C virus is currently unavailable, hepatitis C virus infection can be eradicated by oral direct antiviral agents...
September 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28939993/efficacy-and-prognosis-of-antiviral-therapy-on-hepatitis-c-following-treatment-of-lymphoma-in-hcv-positive-diffuse-large-cell-lymphoma
#3
Yutaka Tsutsumi, Chie Nakayama, Koki Kamada, Ryo Kikuchi, Daiki Kudo, Shinichi Ito, Satomi Matsuoka, Souichi Shiratori, Yoshiya Yamamoto, Hirohito Naruse, Takanori Teshima
The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2)...
September 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28937081/direct-acting-antiviral-drugs-against-hepatitis-c-virus-in-renal-transplant-recipients-is-it-the-dawn-of-an-interferon-free-era
#4
Dharshan Rangaswamy, Shankar P Nagaraju, Ravindra P Attur
Hepatitis C virus (HCV) is a significant problem among hemodialysis population, especially in India where renal transplant often gets delayed in the presence of live-related donors. An acceleration of liver cirrhosis and poor renal allograft outcomes are often witnessed in allograft recipients with high viral load. Use of interferon in the postrenal transplant setting for the treatment of hepatitis C viral infection was limited to a few grave situations, fearing the precipitation of allograft rejection and poor efficacy for sustained virological remission...
September 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28936400/diminishing-use-of-liver-biopsy-among-liver-transplant-recipients-for-hepatitis-c
#5
Elizabeth Aby, Melissa A Jimenez, Jonathan F Grotts, Vatche Agopian, Samuel W French, Ronald W Busuttil, Sammy Saab
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality. Liver biopsies are commonly used to identify recurrent HCV and determine the need for antiviral therapy. The introduction of direct-acting antiviral agents (DAAs) has changed the management of recurrent HCV infection. This study aimed to describe the role of liver biopsies in liver transplant recipients with HCV after the introduction of DAAs...
September 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28935852/single-center-experience-in-pre-transplant-hepatitis-c-virus-hcv-treatment-among-living-donor-liver-transplant-candidates-bridging-the-direct-acting-antivirals-daa
#6
Ashwini M Niranjan-Azadi, Gokhan Kabacam, Christine M Durand, Saad Anjum, Behnam Saberi, Nabil N Dagher, Benjamin Philosophe, Ahmet Gurakar
BACKGROUND Treatment with DAAs before deceased donor liver transplantation has been shown to be an effective strategy to prevent post-transplant HCV recurrence, with a 95% cure-rate among individuals who achieve undetectable HCV VL for ≥30 days pre- transplant. This strategy has not been evaluated in LDLT. MATERIAL AND METHODS We evaluated outcomes in LDLT recipients treated with DAAs pre-transplant and bridged with 4 weeks of post-transplant SOF. All cases of LDLT at Johns Hopkins (1/1/2014-3/1/15) were retrospectively reviewed...
September 22, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28935193/celastrol-inhibits-hepatitis-c-virus-replication-by-upregulating-heme-oxygenase-1-via-the-jnk-mapk-nrf2-pathway-in-human-hepatoma-cells
#7
Chin-Kai Tseng, Sung-Po Hsu, Chun-Kuang Lin, Yu-Hsuan Wu, Jin-Ching Lee, Kung-Chia Young
BACKGROUND AND PURPOSE: Celastrol, a quinone methide triterpene isolated from the root extracts of Tripterygium wilfordii, can greatly induce the gene expression activity of heme oxygenase-1 (HO-1) to achieve disease prevention and control. HO-1 induction was recently shown to result in anti-HCV activity by inducing type I interferon and inhibiting hepatitis C virus (HCV) NS3/4A protease activity. The aim of the present study is to evaluate the anti-HCV activity of celastrol and characterize its mechanism of inhibition...
September 18, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28934424/the-impact-of-hepatitis-b-vaccine-failure-on-long-term-natural-course-of-chronic-hepatitis-b-virus-infection-in-hepatitis-b-e-antigen-seropositive-children
#8
Chi-San Tai, Jia-Feng Wu, Huey-Ling Chen, Yen-Hsuan Ni, Hong-Yuan Hsu, Mei-Hwei Chang
Background: Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in children after universal hepatitis B immunization. This study aimed to investigate the natural course of chronic HBV infection in children with vaccine failure and compare it with that of nonvaccinated children. Methods: Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, who were followed for at least 1 year without antiviral therapy, were enrolled...
September 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28933704/the-association-between-serum-cytokine-and-chemokine-levels-and-antiviral-response-by-entecavir-treatment-in-chronic-hepatitis-b-patients
#9
Mio Kurihara, Masataka Tsuge, Eisuke Murakami, Nami Mori, Waka Ohishi, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yizhou Zhang, Grace Naswa Makokha, C Nelson Hayes, Kazuaki Chayama
BACKGROUND: Although Nucleos(t)ide analogue therapy is thought to suppress chronic hepatitis B(CHB) via regulation of inflammatory cytokines/chemokines, the mechanism is still unclear. In this study, serum cytokine/chemokine levels were measured in CHB patients treated with entecavir, and the association with antiviral response was analyzed. METHODS: Seventy-eight Japanese patients with CHB were enrolled, and serum cytokine/chemokine levels were measured at baseline and at 12, 24, and 48 weeks of entecavir treatment using the MULTIPLEX kit...
September 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28932089/efficacy-and-safety-of-sofosbuvir-and-daclatasvir-in-treatment-of-kidney-transplantation-recipients-with-hepatitis-c-virus-infection
#10
Yan Xue, Li-Xin Zhang, Lei Wang, Tao Li, Yun-Dong Qu, Feng Liu
AIM: To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation (KT) patients with hepatitis C virus (HCV) infection. METHODS: This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with daclatasvir, with or without ribavirin. They were monitored regularly during and after the treatment. RESULTS: Six patients were recruited in our prospective study cohort...
August 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28932081/-epigallocatechin-3-gallate-enhances-poly-i-c-induced-interferon-%C3%AE-1-production-and-inhibits-hepatitis-c-virus-replication-in-hepatocytes
#11
Yi-Zhong Wang, Jie-Liang Li, Xu Wang, Ting Zhang, Wen-Zhe Ho
AIM: To investigate the effect of (-)-epigallocatechin-3-gallate (EGCG) on polyinosinic-polycytidylic acid (poly I:C)-triggered intracellular innate immunity against hepatitis C virus (HCV) in hepatocytes. METHODS: A cell culture model of HCV infection was generated by infecting a hepatoma cell line, Huh7, with HCV JFH-1 strain (JFH-1-Huh7). Poly I:C with a high molecular weight and EGCG were used to stimulate the JFH-1-Huh7 cells. Real-time reverse transcription-polymerase chain reaction was used to detect the expression levels of intracellular mRNAs and of intracellular and extracellular HCV RNA...
August 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28931406/validation-of-a-questionnaire-to-monitor-symptoms-in-hiv-infected-patients-during-hepatitis-c-treatment
#12
Edward R Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks, Wm Christopher Mathews
BACKGROUND: Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy. DESIGN: Five-year retrospective cohort analysis of persons living with HIV (PLWH) treated for HCV. METHODS: The HCV symptom-inventory (HCV-SI) was administered before, during, and after HCV treatment. Discriminant validity was assessed, separately, in mixed model linear regression of HCV-SI T-scores on treatment regimens (pegylated-interferon and ribavirin; pegylated-interferon, ribavirin, and telaprevir; and interferon-free antivirals); and side effect-related premature treatment discontinuation (SE-DC)...
September 20, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28929515/treatment-of-hepatitis-c-virus-infection-with-direct-acting-antiviral-drugs-is-safe-and-effective-in-patients-with-hemoglobinopathies
#13
Raffaella Origa, Maria Laura Ponti, Aldo Filosa, Alfonso Galeota Lanza, Antonio Piga, Giorgio Maria Saracco, Valeria Pinto, Antonino Picciotto, Paolo Rigano, Salvatore Madonia, Rosamaria Rosso, Domenico D'Ascola, Maria Domenica Cappellini, Roberta D'Ambrosio, Immacolata Tartaglione, Lucia De Franceschi, Barbara Gianesin, Vito Di Marco, Gian Luca Forni
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few...
September 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28927676/a-pilot-study-to-expand-treatment-of-chronic-hepatitis-c-in-resource-limited-settings
#14
REVIEW
Poonam Mathur, Emily Comstock, Edward McSweegan, Natalia Mercer, Nongthombam Suraj Kumar, Shyamasundaran Kottilil
The past five years have seen a revolution in the treatment of chronic hepatitis C, as short duration oral regimens of direct-acting antiviral drugs (DAAs), with nearly 100% cure rates for all genotypes, have replaced longer courses of ribavirin and injected interferon. Although initially very expensive, these DAAs are now becoming available in generic equivalents in countries with large numbers of chronically infected people, such as India. However, a number of obstacles may hinder the delivery of these drugs in resource-limited settings, including lack of access to diagnostic testing and the restriction of treatment to a small number of medical specialists...
September 16, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28927498/drug-treatment-for-chronic-hepatitis-c-infection-and-cancer-risk
#15
Marcus-Alexander Wörns, Peter Robert Galle, Stefan Zeuzem, Peter Schirmacher, Michael Manns, Arndt Vogel
BACKGROUND: In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy...
September 4, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28926562/generics-for-the-treatment-of-hepatitis-c-in-monoinfected-and-hiv-coinfected-patients-pros-and-cons
#16
Dario Cattaneo, Alessandro Fossati, Chiara Resnati, Massimo Galli, Cristina Gervasoni
The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28925824/can-we-go-for-a-shorter-treatment-course-in-chronic-hepatitis-c-more-inspiring-cases
#17
Rosa Zampino, Martina Vitrone, Antonio Parrella, Enrico Ragone, Emanuele Durante-Mangoni
Current interest in HCV therapy with direct acting antivirals is focused on shortening treatment length. We managed two cirrhotics who achieved virological cure after 4 weeks of ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin treatment. Analysis to identify potential predictive factors for a successful outcome with a shorter treatment course was conducted.
September 19, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28925068/when-and-how-can-nephrologists-treat-hepatitis-c-virus-infection-in-dialysis-patients
#18
REVIEW
Maya I Davis, Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus (HCV) infection, a major cause of end-stage liver disease, is a common comorbidity in patients on dialysis and causes increased morbidity and mortality. Historically HCV has been extremely difficult to cure with interferon and ribavirin-based therapies, which are also associated with significant side effects, and few dialysis patients ever received HCV treatment. However, in the last 4 years, interferon-free direct-acting antiviral therapies have been approved, and several combinations have been studied in dialysis patients...
September 18, 2017: Seminars in Dialysis
https://www.readbyqxmd.com/read/28924449/outcomes-after-sofosbuvir-containing-regimens-for-hepatitis-c-virus-in-patients-with-decompensated-cirrhosis-a-real-world-study
#19
Fanpu Ji, Wenjun Wang, Shuangsuo Dang, Shengbang Wang, Burong Li, Dan Bai, Wenxue Zhao, Hong Deng, Changyin Tian, Zongfang Li
BACKGROUND: Direct-acting antivirals have been used for decompensated cirrhotic patients with hepatitis C virus (HCV) infection. However, the benefits in Chinese patients with decompensated cirrhosis are unclear. METHODS: Thirty patients with HCV infection and decompensated cirrhosis were administered sofosbuvir-containing regimens at our hospital between April and December 2015. The efficacy and safety of the treatments was determined by sustained virological response at week 12 (SVR 12), change of liver function and adverse events...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28923507/pentagalloylglucose-a-highly-bioavailable-polyphenolic-compound-present-in-cortex-moutan-efficiently-blocks-hepatitis-c-virus-entry
#20
Patrick Behrendt, Paula Perin, Nicolas Menzel, Dominic Banda, Stephanie Pfaender, Marco P Alves, Volker Thiel, Phillip Meulemann, Che C Colpitts, Luis M Schang, Florian W R Vondran, Anggakusuma, Michael P Manns, Eike Steinmann, Thomas Pietschmann
Approximately 142 million people worldwide are infected with hepatitis C virus (HCV). Although potent direct acting antivirals are available, high costs limit access to treatment. Chronic hepatitis C virus infection remains a major cause of orthotopic liver transplantation. Moreover, re-infection of the graft occurs regularly. Antivirals derived from natural sources might be an alternative and cost-effective option to complement therapy regimens for global control of hepatitis C virus infection. We tested the antiviral properties of a mixture of different Chinese herbs/roots named Zhi Bai Di Huang Wan (ZBDHW) and its individual components on HCV...
September 15, 2017: Antiviral Research
keyword
keyword
68490
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"